{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" \"PATHOLOGY\": []", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" \"PATHOLOGY\": [\"retroperitoneal liposarcoma\", \"rhabdomyolysis\"]", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" \"PATHOLOGY\": [\"abdominal mass\"]\n\nThis information indicates that the patient underwent a surgical procedure to remove an abdominal mass, achieving a complete removal (R0 resection). No further information about the nature of the mass or the underlying condition is provided in the text.", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" \"PATHOLOGY\": [\"lesion\"]\n\nThis information does not provide enough context to determine if it refers to a specific disease or condition.", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" \"PATHOLOGY\": []", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" \"PATHOLOGY\": [\"cancer\"]", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" \"PATHOLOGY\": []", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" \"PATHOLOGY\": []", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" \"PATHOLOGY\": [\"chronic back pain\"]\n\n\"GENES\": [\"COMT\", \"HTR2A\"]", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" \"PATHOLOGY\": [\"Parkinson's disease\"]", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathology or side effect. It only discusses the importance of considering cannabis, pharmacokinetics, pharmacodynamics, and pharmacogenomics in evaluating a patient's medication regimen.", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" \"PATHOLOGY\": [\"PD\", \"spinal stenosis\", \"vitamin D deficiency\", \"frequent falls\", \"history of nicotine and alcohol dependence\", \"mild kidney disease\", \"chronic neck, back, and shoulder pain\"]", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" \"PATHOLOGY\": [\"tremors\"]", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" \"PATHOLOGY\": []", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" \"\"PATHOLOGY\" : []\n\nThis passage does not mention any specific pathology or disease. It is discussing various factors that can lead to discrepancies in study results.", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" \"PATHOLOGY\": []\n\nThis statement does not mention any specific pathology or side effect. It is discussing the effects of CB1Rs on neurotransmitter levels.", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" \"PATHOLOGY\": [\"\"]\n\n(Note: COMT is an enzyme and does not directly correspond to a specific pathology or disease)", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" \"PATHOLOGY\": [\"Parkinson's disease\"]", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" \"PATHOLOGY\": [\"\"]\n\n(In this context, no specific pathology or disease is mentioned, as the passage is discussing a specific patient's treatment with morphine based on their genetic results and CYP2D6 metabolism.)", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" {}\n\nThere is no mention of a specific pathology or side effect in this statement.", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" \"PATHOLOGY\": []", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" \"PATHOLOGY\": [\"cancer\"]", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" It is not clear what is being reported as having a range from 29% to 83% in the given context. Therefore, no pathology can be identified from this information.", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" \"PATHOLOGY\": []\n\nThis statement does not refer to a specific disease or condition. It is a general statement about the drugs in question.", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" \"PATHOLOGY\": []", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" \"PATHOLOGY\": []", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" \"PATHOLOGY\": [\"hypoglycemia\"]\n\n\"GENETICS\": [\"rs1142345 (A>G) SNP\", \"thiopurine S-methyltransferase (TPMT) gene\"]", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" \"PATHOLOGY\": [\"diabetes\"]\n\nThis information mentions the association of rs1142345 with the clinical effect of traditional hypoglycemic herbs in the context of diabetes.", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" {\"PATHOLOGY\": [],\n \"PHARMACOKINETICS\": [\"AUC: concentration-time curve\", \"EMs: extensive metabolizer\", \"PM: poor metabolizer\"]}", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" \"PATHOLOGY\": []\n\n(No specific pathologies or side effects mentioned in the text)", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" \"PATHOLOGY\": []", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" \"PATHOLOGY\": []\n\n(Note: The term \"xenobiotics\" refers to foreign substances that are present in an organism and are not naturally produced by the body. The term \"endogenous substances\" refers to substances produced naturally within the body. In this context, the text is discussing the role of CYP450 enzymes in the metabolism of these substances, so no specific pathologies or side effects are mentioned.)", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in the provided text.)", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" No pathologies or side effects were mentioned in this text.", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" No new pathologies were mentioned in this text.", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" \"PATHOLOGY\": []", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" \"\"PATHOLOGY\" : []\n\nThe text does not mention any specific pathology or side effect related to the TDI (toxicity due to drug-herb interaction) effects of herbals.", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" No pathology mentioned in this text.", {}]], [38, "[44].", [" It is unclear what information is provided in reference [44] as it is not included in the text. Therefore, there is no information to parse for pathologies or entities.", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" This passage does not contain any references to specific pathologies or side effects. Therefore, there is no need to include a \"PATHOLOGY\" field in the output. The text describes a method used to evaluate the inhibition of CYP2B6 enzyme activity by medicinal plant extracts. The method involves the use of a Waters Acquity UPLC system, an Acquity BEH C18 column, a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector.", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" \"PATHOLOGY\": []", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" \"PATHOLOGY\": []", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" \"PATHOLOGY\": []", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" \"PATHOLOGY\": []", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" \"PATHOLOGY\": [\"type 2 diabetes\"]", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" \"PATHOLOGY\": [\"diabetic patients\"]", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" \"PATHOLOGY\": []\n\n(This passage does not mention any specific pathology or side effect.)", {}]], [47, "Elliot et al.", [" \"PATHOLOGY\": [] # No pathology information was provided in the context given.", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" \"PATHOLOGY\": [\"\"]\n\n(No relevant pathologies or side effects were mentioned in this text.)", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" No specific pathology mentioned in the text.", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology or entity mentioned in this text.)", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" It is unclear what \"2003\" refers to in the context of the cited entities. Therefore, it should not be included in the output.\n\nThe final output:\n{\"PATHOLOGY\": [\"CKD\", \"menopausal symptoms\", \"menopausal\", \"type 2 diabetes\", \"hypertension\", \"HIV\", \"HIV-associated opportunistic infections\"]}", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" \"PATHOLOGY\": [\"CYP2C9\"]\n\n\"GENETIC VARIANT\": [\"CYP2C9\\*3\"]\n\n\"DRUG\": [\"glipizide\", \"tolbutamide\"]", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" \"PATHOLOGY\": [] # No pathology information provided in the given context.", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" \"PATHOLOGY\": [\"acute cytomegalovirus (CMV)\", \"Epstein Barr virus (EBV)\"]\n\nNote: In this context, \"serological titers for\" indicates the presence of antibodies to the viruses, indicating past or current infection. Negative results mean no antibodies were detected, indicating no past or current infection.", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" \"PATHOLOGY\": [\"antinuclear antibody\", \"smooth muscle antibody\"]", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" \"PATHOLOGY\": [\"chronic hepatitis\", \"fibroinflammatory expansion of portal tracts\", \"moderate plasma cell rich interface hepatitis\", \"rare periportal hepatocyte apoptosis\", \"mild cholangiolar proliferation\"]", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" \"PATHOLOGY\": []\n\nThis sentence does not provide any information about a specific pathology or condition. It is just stating that the clinical features of a case are presented in the tables.", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" \"PATHOLOGY\": [\"abdominal pain\", \"fatigue\", \"edema\"]", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" \"PATHOLOGY\": [\"menopause\"]", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" \"PATHOLOGY\": [\"liver failure\"]", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" \"PATHOLOGY\": [\"autoimmune response\"]", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" \"PATHOLOGY\": []\n\nThis citation refers to a specific tool or scale used to evaluate adverse drug reactions, rather than a specific disease or condition.", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" \"PATHOLOGY\": [\"hepatotoxicity\"]", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" \"PATHOLOGY\": [\"bacterial infections\"]\n\nNote: The term \"bacterial infections\" is a general term and does not refer to a specific disease or condition. It is included here to maintain consistency with the original text.", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" \"PATHOLOGY\": [\"urinary system infection\"]", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" \"PATHOLOGY\": []", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" No pathologies or side effects mentioned in this text.", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" {}\n\n\"PATHOLOGY\": []\n\n(This line does not contain any information about a pathology or side effect.)", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" \"PATHOLOGY\": []", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" No pathologies or side effects were mentioned in this text.\n\n\"PATHOLOGY\": []", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" \"PATHOLOGY\": []", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" {}\n\n\"PATHOLOGY\": []\n\n(This passage does not contain any specific reference to a pathology or side effect.)", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" \"PATHOLOGY\": []", {}]], [74, "KY[2017]073).", [" This is likely a citation for a specific document or publication. It does not provide any information about pathologies or entities. Therefore, the \"PATHOLOGY\" field should be left empty for this entry.", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" \"PATHOLOGY\": [\"diabetes\"]", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" \"PATHOLOGY\": [\"cancer\"]\n\n\"PATHOLOGY\": [\"osteoporosis\"]\n\n\"PATHOLOGY\": [\"inflammation\"]", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" No pathologies or side effects found in this text.", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" \"PATHOLOGY\": []\n\nThis passage does not contain any specific reference to a pathology or side effect. It is describing a laboratory experiment using digoxin and MDCK-II cells.", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" {\"PATHOLOGY\": []}\n\nThis passage does not mention any specific pathologies or side effects. It only discusses the compounds isolated from the roots of KF (KF being an unspecified medicinal plant).", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" No pathology or entity mentioned in this text.", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" \"PATHOLOGY\": [\"diabetes\", \"hypoglycemia\", \"hypoglycemic drugs\", \"thiazolidinediones (TZDs)\", \"sulfonylureas\", \"cholesterol\", \"hypocholesterolemic drugs\", \"atorvastatin\"]", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" \"PATHOLOGY\": [\"diabetes\", \"obesity\"]", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" \"PATHOLOGY\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" \"PATHOLOGY\": []", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It is only reporting the inhibition of certain enzymes (CYP2C8, CYP2C9, and CYP3A4) by GRT and FRE.", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" \"PATHOLOGY\": [\"xenobiotic and endogenous compounds\"]\n\n\"BIOCHEMICAL PROCESS\": [\"phase I metabolism\"]\n\n\"ENTITY\": [\"CYP2C9\", \"IC\"]\n\n\"ENTITY (CYP2C9)\": {\n\"ROLE\": [\"plays a role in the oxidation of xenobiotic and endogenous compounds\", \"is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism\"]\n}\n\n\"ENTITY (IC)\": {\n\"DESCRIPTION\": [\"inhibition constant\"]\n}\n\n\"ENTITY (GRT)\": {\n\"PROPERTY\": [\"higher levels of polyphenols\", \"containing\", \"ASP (12.78%)\"]\n}\n\n\"ENTITY (FRE)\": {\n\"PROPERTY\": [\"lower levels of polyphenols\", \"containing\", \"ASP (0.36%)\"]\n}\n\n\"ENTITY (ASP)\": {\n\"DESCRIPTION\": [\"polyphenol\"]\n}\n\n\"ENTITY (CYP3A4)\": {\n\"ROLE\": [\"enzyme\"]\n}", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" No pathology mentioned in the text.", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" \"PATHOLOGY\": []\n\nThis information does not provide any new pathologies or side effects. It only mentions the inhibitors of certain cytochrome P450 enzymes (CYP2C8, CYP2C9, and CYP3A4).", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific diseases or conditions. It only mentions the use of nutraceuticals containing rooibos extracts and their potential interaction with drugs metabolized by CYP2C8 and CYP3A4.", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" No pathologies or entities were mentioned in this statement. Therefore, the \"PATHOLOGY\" field should be left empty.", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" \"PATHOLOGY\": []", {"Herb name": ["Echinacea"]}]], [94, "2).", [" I'm assuming you're asking for the second entry in the article. Here's the information for it:\n\n\"The purpose of this study was to evaluate the inhibition of CYP2B6 enzyme activity by selected medicinal plant extracts used by HIV patients to treat HIV-associated opportunistic infections.\"\n\n\"PATHOLOGY\": [\"HIV\", \"HIV-associated opportunistic infections\"]\n\nThis entry does not contain any new information for entities that have already been mentioned.", {}]], [95, "This result was statistically not significant.", [" {}\n\n\"PATHOLOGY\": []\n\n(Since no specific pathology was mentioned in the context of this statement, an empty list is provided.)", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" \"PATHOLOGY\": []", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" \"PATHOLOGY\": []", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" \"PATHOLOGY\": [\"toxicities\"]\n\n\"TOXICITIES\": [\"grade 3 and 4\"]\n\n\"PATHOLOGY\": [\"docetaxel\"]\n\n\"PATHOLOGY\": [\"NCI CTCAE\", \"version 3.0\"]", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" No pathology mentioned in the text.\n\n{\"PATHOLOGY\": []}", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" \"PATHOLOGY\": []", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathology or side effect. It is only discussing the statistical analysis of the study.", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" \"PATHOLOGY\": []", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology mentioned in this text)", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" \"PATHOLOGY\": []", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" \"PATHOLOGY\": []", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" \"PATHOLOGY\": [\"E. purpurea\"]\n\n\"ENTITY\": [\"roots\", \"leaves\"]\n\n\"COMPOUND\": [\"alkylamides\", \"DTAI\"]\n\n\"PARTS\\_OF\\_PLANTS\": [\"roots\", \"leaves\"]\n\n\"QUANTITY\\_VARIATION\": [\"alkylamide content\"]\n\n\"LOCATION\\_VARIATION\": [\"parts of E. purpurea plants\"]\n\n\"COMPOUND\\_VARIATION\": [\"DTAI are more abundant in roots than in leaves\"]\n\nNote: I added some additional fields to provide more context and information about the text.", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" \"PATHOLOGY\": [\"\"]\n\n(In this context, there is no clear reference to a specific pathology or disease.)", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" \"PATHOLOGY\": [\"\"]\n\n(In this context, there is no clear reference to a specific pathology or side effect.)", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" \"PATHOLOGY\": [\"cancer patients\"]\n\nNote: P-gp is a protein, not a disease or condition, so it does not belong in the \"PATHOLOGY\" category. However, I included \"cancer patients\" since they were mentioned in the context of the discussion about P-gp inhibitors.", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" \"PATHOLOGY\": [\"advanced cancer\"]", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology or side effect mentioned in this sentence)", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" \"PATHOLOGY\": [\"p-glycoprotein\"]\n\nThe gene encoding p-glycoprotein is ABCB1.", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" No specific pathologies mentioned in this text.", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" This text does not contain any information about pathologies or side effects.", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathology or side effect. It is discussing the methodology used in the study, specifically the generation of a calibration curve range for certain compounds using LC-MS/MS.", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" \"PATHOLOGY\": [\"blood\"]\n\nThis statement does not mention any specific disease or condition. The DNA isolation is likely being done for a research or diagnostic purpose, but it does not provide enough information to determine the specific pathology.", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathologies or side effects. It only mentions the identification of single-nucleotide polymorphisms (SNPs) in the ABCB1 gene.", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" \"PATHOLOGY\": []", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" \"PATHOLOGY\": []", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathologies or side effects. It is discussing the pharmacokinetics of digoxin and green tea catechins (GTC) in relation to each other.", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" \"PATHOLOGY\": [\"digoxin\"]\n\n\"DRUG\": [\"GTC\"]\n\n\"GENETIC\\_MARKER\": [\"ABCB1\"]", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" \"PATHOLOGY\": [\"digoxin\"]", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" \"PATHOLOGY\": []\n\nThis passage does not provide any information about specific pathologies or diseases. It is discussing the presentation of data in a study.", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" \"PATHOLOGY\": [\"methotrexate\"]\n\nThis information does not provide any additional pathologies or side effects beyond methotrexate.", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" \"PATHOLOGY\": []", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" \"PATHOLOGY\": []", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" {\"PATHOLOGY\": []}", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathologies or side effects were mentioned in this text.)", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" \"PATHOLOGY\": [\"rheumatoid arthritis\"]", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" \"PATHOLOGY\": [\"rheumatoid arthritis\"]", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" \"PATHOLOGY\": []", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" No pathology mentioned in this text.", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" No pathology mentioned in the text.", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" No pathology mentioned in this statement.", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" \"PATHOLOGY\": []", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" \"PATHOLOGY\": []", {}]], [137, "Contents of ginsenosides in RGE.", [" \"PATHOLOGY\": []\n\nThis sentence does not refer to any specific pathology or side effect. It is discussing the contents of ginsenosides in Red Ginseng (RGE).", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" \"PATHOLOGY\": []", {}]], [139, "2014; Dybro et\u00a0al.", [" \"PATHOLOGY\": []", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" \"PATHOLOGY\": []", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" No pathology or entity mentioned in this text.", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" No pathologies or side effects mentioned in this text.\n\n\"PATHOLOGY\": []", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" \"PATHOLOGY\": []", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" No pathology mentioned in this sentence.", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" No pathology mentioned in this text.", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" \"PATHOLOGY\": []", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" No pathology mentioned in this text.", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" \"PATHOLOGY\": []", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" \"PATHOLOGY\": []", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" \"PATHOLOGY\": []", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" \"PATHOLOGY\": []", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" \"PATHOLOGY\": [\"neonates\", \"patients with renal dysfunction\"]", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" I cannot directly parse the literature for you, but based on the context provided, it seems that the literature discusses the interaction between Traditional Chinese Medicine (TCM) formulations and digoxin. Therefore, no specific pathologies or entities are mentioned in this context.\n\nHowever, for completeness, I will provide a general list of entities related to TCM and digoxin:\n\n{\"PATHOLOGY\": [],\n \"TCM\": [\"Traditional Chinese Medicine\"],\n \"digoxin\": [\"digoxin\"]}", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" \"PATHOLOGY\": [\"rats\"]\n\n\"ENTITY\": [\n\"Conioselinum anthriscoides 'Chuanxiong'\",\n\"Vernonia amygdalina 'Biantaobanjiuju'\",\n\"Tapinanthus sessilifolius\",\n\"Carica papaya 'Mugua'\",\n\"Ginkgo biloba L. 'Yinxing'\"\n]", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology mentioned in the text)", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" \"AUTHOR\": [\"Li Xin\"]\n\nThis information does not provide any pathology or side effect information.", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" \"PATHOLOGY\": [\"arrhythmia\", \"ventricular arrhythmias\", \"digoxin-induced arrhythmias\"]\n\n\"ENTITIES\": [\n\"C. pinnatifida Bunge (Shanzha)\",\n\"flavonoid glycoside\",\n\"flavane polymers\",\n\"digoxin\"\n]", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" \"PATHOLOGY\": [\"\"]\n\n(Note: The given text does not mention any specific pathology or side effect related to pharmacology.)", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology or side effect mentioned in the text)", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" \"PATHOLOGY\": []", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology or side effect mentioned in the text)", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" \"PATHOLOGY\": []\n\nThis statement does not directly refer to any specific pathology or disease. It discusses the potential for herb-drug interactions.", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" \"PATHOLOGY\": []\n\n(This passage does not mention any specific pathology or side effect.)", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" \"PATHOLOGY\": []\n\nThis statement does not mention any specific pathology or disease. It is discussing metabolic drug interactions in general.", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" \"PATHOLOGY\": []", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" \"PATHOLOGY\": []", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" \"PATHOLOGY\": []", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" No pathologies or side effects were mentioned in this text.", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" \"PATHOLOGY\": []", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" No pathology mentioned in the text.", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathology or disease. It is discussing the determination of the inhibitory potential of a plant extract (CAW-R61J) on the activity of a specific enzyme (P450).", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" {}\n\n\"PATHOLOGY\": []\n\n(This line is empty as no specific pathology or entity is mentioned in this sentence.)", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" This text does not provide any information about pathologies or side effects.", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" I apologize for the confusion, but the context provided does not allow me to determine the exact entities being referred to in the phrase \"2 above (substituting logEC50 for logIC50)\". The abbreviations \"logEC50\" and \"logIC50\" are commonly used in pharmacology to represent the logarithm of the concentration of a substance that results in 50% inhibition or 50% inhibition constant, respectively. However, without additional context, it is impossible to determine the specific pathologies or entities related to this study. Therefore, I cannot provide a valid answer for this query.", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" No pathology or side effects were mentioned in this text.", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" I cannot parse any pathologies from this line as it is just a reference to a figure.", {}]], [177, "Mean\tS.D.", [" \"STATISTICS\": [\"Mean\", \"Standard Deviation\"]\n\nPlease note that this information was not provided in the context of the given text, but rather it is a common statistical term.", {}]], [178, "Mean\tS.D.", [" \"STATISTICS\": [\"Mean\", \"Standard Deviation\"]\n\nPlease note that this information was not provided in the context of the given text, but rather it is a common statistical term.", {}]], [179, "***P < 0.0001.", [" This is a statistical value and does not refer to a specific pathology or entity. It indicates the level of significance in the results of a statistical analysis.", {}]], [180, "; data not shown).", [" {}\n\nThis line does not contain any information about pathologies or entities. It is likely a note indicating that data is not presented in the text.", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" I'm unable to extract specific pathologies or entities from this statement as it is just referencing literature. However, some of the cited literature may be related to pharmacology or drug interactions.\n\n\"PATHOLOGY\": []", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" \"PATHOLOGY\": []\n\n(Note: No specific pathologies or side effects were mentioned in this text.)", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or identify entities from an external file. The information provided in the text should be sufficient for entity identification.", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" I cannot parse any pathologies from this line as it is just a reference to a figure object name.", {}]], [185, "Data shown are the means \u00b1 S.D.", [" No pathology or entity identified in this statement.", {}]], [186, "of triplicate determinations.", [" {}\n\nThis text does not contain any mention of a specific pathology or side effect.", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathologies or side effects were mentioned in this text.)", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" No pathology mentioned in this text.", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" \"PATHOLOGY\": []", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" \"PATHOLOGY\": []", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" \"PATHOLOGY\": []", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" \"PATHOLOGY\": [\"hypertension\", \"chronic kidney disease\"]", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" No pathologies or side effects were mentioned in this text.", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" \"PATHOLOGY\": []", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" No pathologies or side effects were mentioned in this text.\n\nTherefore, the output will be an empty dictionary.\n\n{\"PATHOLOGY\": []}", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" \"PATHOLOGY\": []", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" \"PATHOLOGY\": []", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" No pathology mentioned in the text.\n\n{\"PATHOLOGY\": []}", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or disease. It is describing a method for analyzing amlodipine.", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" No pathologies or side effects were mentioned in this text.\n\nTherefore, the output will be an empty dictionary.\n\n{\"PATHOLOGY\": []}", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" \"PATHOLOGY\": []", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" \"PATHOLOGY\": []\n\nThis passage does not contain any specific references to pathologies or side effects. It is discussing the accuracy of a bioanalytical method and the acceptance criteria for accuracy set by regulatory agencies.", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" \"PATHOLOGY\": [\"hypertension\"]", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" \"PATHOLOGY\": []", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" I'm assuming \"M.P.\" stands for \"Medical Professional\" or \"Master of Pharmacy.\" No pathology or disease entity is mentioned in the given context.\n\n{\"PATHOLOGY\": []}", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" No pathology mentioned in this text.", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" \"PATHOLOGY\": [\"chronic nature of HAART administration\"]\n\nHAART stands for Highly Active Antiretroviral Therapy, which is a treatment for HIV (Human Immunodeficiency Virus).", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" \"PATHOLOGY\": [\"people taking ART\"]\n\nThis refers to individuals living with HIV/AIDS who are undergoing Antiretroviral Therapy.", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" \"PATHOLOGY\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhea\", \"dyslipidemia\", \"headache\"]", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" \"PATHOLOGY\": []", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" \"PATHOLOGY\": []", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" \"PATHOLOGY\": [\"genetic polymorphism\"]\n\n\"PATHOLOGY\": [\"xenobiotics\"]", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" \"PATHOLOGY\": []", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" {\"CHEMICAL COMPOUNDS\": [\"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\", \"p-Coumaric acid\"]}", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" \"PATHOLOGY\": []", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" {\"PATHOLOGY\": []}\n\nThis passage does not mention any specific diseases or conditions. It only refers to the plant extracts and their inhibition of CYP2B6 enzyme activity.", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" \"PATHOLOGY\": []", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" No pathologies or side effects were mentioned in this text.", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" \"PATHOLOGY\": []", {}]], [220, "All authors reviewed the final manuscript.", [" No pathologies or side effects were mentioned in this text.\n\n\"PATHOLOGY\": []", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in the given context.)", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" No pathology mentioned in this text.", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" No pathology mentioned in the text.", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" \"PATHOLOGY\": [\"common cold\"]", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" I cannot determine any pathologies or side effects from this text as it only mentions the use of two medications (AAP and GGT) and their dosages in simulation scenarios.", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" \"PATHOLOGY\": []", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" I'm unable to determine the meaning of \"Y.C.P.\" without additional context. Please provide more information for proper parsing.", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" I cannot extract any pathologies or entities from this text as it only lists names of individuals.", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" \"PATHOLOGY\": []\n\n\"PK\": [\"AAP\"]\n\nNote: \"PK\" stands for Pharmacokinetics, which is a field of pharmacology that deals with the absorption, distribution, metabolism, and excretion of drugs within the body. In this context, \"AAP\" likely refers to a specific drug or active pharmaceutical ingredient.", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" \"PATHOLOGY\": [\"elderly subjects\"]\n\n\"PATHOLOGY\": [] (No specific diseases or conditions mentioned in this context)", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific diseases or conditions. It only talks about herbal supplement usage among older adults and those taking prescription medications.", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" \"PATHOLOGY\": [\"elders\"]", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" No pathologies or side effects were mentioned in this text.", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" No pathology mentioned in the text.", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" {}\n\n\"PATHOLOGY\": []\n\nThis section does not provide any information about pathologies or side effects.", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" This table does not provide any information about pathologies or side effects. It only presents data on phenotypic ratios and supplements.", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" \"PATHOLOGY\": []", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" No pathology mentioned in this statement.", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" \"PATHOLOGY\": []\n\n(This passage does not mention any specific pathology or side effect.)", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" \"PATHOLOGY\": []", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" \"PATHOLOGY\": [\"elderly patients\", \"anticoagulant therapy\"]", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" \"PATHOLOGY\": [\"platelet activating factor\"]", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" \"PATHOLOGY\": []", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" \"PATHOLOGY\": []", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" \"PATHOLOGY\": []\n\nThis statement does not mention any specific pathology or disease. It is a general statement about herb-drug interactions.", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" \"PATHOLOGY\": []", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" {\"CHEMICAL COMPONENTS\": [\"benxophenones\", \"xanthones\", \"alkaloids\", \"phenols\", \"tannins\", \"saponins\", \"kolaviron\", \"biflavonoid complex\", \"aluminum\", \"magnesium\", \"calcium\", \"copper\"]}", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" \"PATHOLOGY\": [\"pregnancy\", \"breastfeeding\", \"hypersensitivity to quinine or similar agents\"]\n\nNote: \"adverse side effects from taking G. kola seeds\" is already implied by \"hypersensitivity to quinine or similar agents\". Therefore, it is not necessary to include it separately in the list.", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" {}\n\n\"PATHOLOGY\": []\n\nThis passage does not mention any specific pathologies or side effects. It only describes the inclusion criteria for the study participants.", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" \"PATHOLOGY\": []", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" {}\n\"PATHOLOGY\": []\n\nThis passage is not about specific pathologies or side effects. It is describing the procedure for collecting blood samples.", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" No pathology mentioned in the text.", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" \"PATHOLOGY\": []", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" \"PATHOLOGY\": []", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" \"PATHOLOGY\": []\n\nExplanation: The text does not mention any specific pathology or side effect related to the entities mentioned.", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" \"PATHOLOGY\": []", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" \"PATHOLOGY\": []", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" {}\n\n\"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or condition. It is only describing the number of participants and their assignment to a treatment group in a study.", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" \"PATHOLOGY\": [\"HIV\", \"adults\"]\n\n\"TCAM\": [] # This is a term for Traditional Complementary and Alternative Medicine, so it's not a disease or side effect, but it's important to include it in the output for completeness.", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" \"PATHOLOGY\": []\n\nThis statement does not mention any specific pathology or disease. It refers to the results of a study using the MOS-HIV (Mental Health Inventory for HIV) questionnaire, comparing the placebo group to a group receiving 1200mg of a treatment.", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" {}\n\"PATHOLOGY\": []\n}\n\nThis passage does not mention any specific pathologies or conditions.", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" {}\n\n\"PATHOLOGY\": []\n}\n\nThis text does not contain any specific pathologies or side effects. The abbreviations refer to types of lipoproteins.", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" I cannot directly access or parse the contents of the linked PDF file. Please provide the necessary information directly in the text for entity parsing.", {}]], [265, "Thabethe, D.A.", [" \"AUTHOR\": [\"Thabethe, D.A.\"]\n\nNote: In scientific articles, entities related to authors are typically not included in the \"PATHOLOGY\" field.", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" \"PATHOLOGY\": []", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" \"PATHOLOGY\": [\"chronic kidney disease (CKD)\"]", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It only states that some therapies can be harmful due to drug interactions.", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" \"PATHOLOGY\": []", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" \"PATHOLOGY\": []", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" \"PATHOLOGY\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"]", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" \"PATHOLOGY\": []", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" {}\n\"PATHOLOGY\": []\n}\n\nThis sentence does not mention any specific disease or condition. It only refers to the age group of the patients in a previous study.", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" \"PATHOLOGY\": [\"common cold\", \"respiratory problems\"]", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" It is not possible to determine the pathology from the given information. The reference [27] only provides the name of the authors who conducted a study.", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" \"PATHOLOGY\": []", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" \"PATHOLOGY\": [\"residual tumor\"]", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" \"PATHOLOGY\": []", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" No pathologies or side effects mentioned in this text.\n\n\"PATHOLOGY\": []", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" \"PATHOLOGY\": [\"International normalized ratio\"]", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" No specific pathology mentioned in this text.\n\n\"PATHOLOGY\": []", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" No pathologies or side effects mentioned in this text.", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" {}\n\"PATHOLOGY\": [],\n\"PHARMACOLOGY\": [\"S-warfarin\", \"prothrombin complex activity\", \"INR\"]\n}", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" (No pathology mentioned in this context)", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" \"PATHOLOGY\": []\n\n\"CYP2B6 enzyme activity\": [\"CYP2B6\"]\n\n\"Medicinal plant extracts\": []\n\n\"HIV patients\": [\"HIV\"]\n\n\"HIV-associated opportunistic infections\": [\"opportunistic infections\"]\n\nThe table provides pharmacokinetic parameters for S-warfarin and R-warfarin with different interactions:\n\n- Warfarin only\n- Warfarin and cranberry\n- Warfarin and garlic\n\nThe columns in the table include:\n\n- tmax (hours to reach maximum concentration)\n- Cmax (maximum concentration)\n- t1/2 (half-life)\n- AUC (area under the plasma concentration-time curve)\n- CL/F (apparent clearance)\n- Fraction unbound\n\nFor each parameter, the mean, geometric mean ratio, and 90% confidence interval are provided for warfarin only, warfarin and cranberry, and warfarin and garlic.", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" {}\n\"PATHOLOGY\": []\n}\nThis information does not provide any mention of specific pathologies or side effects. It is about the presentation of pharmacokinetic-pharmacodynamic modeling results for warfarin.", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" \"(2006b)\" is a citation and does not provide any information about pathologies.\n\n\"PATHOLOGY\": []", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" \"PATHOLOGY\": [\"cancer\"]", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" \"PATHOLOGY\": [\"Valeriana officinalis\"]\n\n\"DRUG\": [\"CYP 3A4\"]\n\n\"INTERACTION\": [\"may stimulate\"]\n\nNote: Since \"INTERACTION\" is not a pathology, it is included here as an additional information.", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" \"PATHOLOGY\": [\"elderly\"]", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" {}\n\n\"PATHOLOGY\": []\n\nThis information does not provide any reference to a specific pathology or side effect.", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" No pathology mentioned in this text.", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" \"PATHOLOGY\": []", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" \"PATHOLOGY\": []", {}]], [298, "[36].", [" It is unclear what information is associated with this number in the text. Therefore, no entities can be identified from this part of the text.", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" No pathologies or side effects were mentioned in this text.", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathologies or side effects were mentioned in this text.)", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" \"PATHOLOGY\": []\n\n(This passage does not mention any specific pathology or disease)", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" \"PATHOLOGY\": []", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" \"PATHOLOGY\": []", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" \"PATHOLOGY\": [\"delirium\"]", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" \"PATHOLOGY\": []", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" \"PATHOLOGY\": []", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" \"PATHOLOGY\": []", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" \"PATHOLOGY\": []", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" \"PATHOLOGY\": [\"\"]\n\n(This passage does not mention any specific pathology or side effect.)", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" \"PATHOLOGY\": []", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" No pathology or entity mentioned in this statement.", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" \"PATHOLOGY\": [\"rifampin\", \"clarithromycin\"]\n\nThese are antibiotics used for controlling bacterial infections.", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" \"PATHOLOGY\": [\"depression\"]", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" \"PATHOLOGY\": [\"radiological abnormalities\"]\n\n\"PATHOLOGY\": [\"LVEF\"] (Left Ventricular Ejection Fraction)", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" \"PATHOLOGY\": [\"cardiopulmonary toxicity\"]", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" \"PATHOLOGY\": [\"DIP\"]\n\n\"DIP\": [\"drug-induced pigmentation\"]\n\nNote: In this context, \"DIP\" refers to drug-induced pigmentation.", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" \"PATHOLOGY\": [\"cardiopulmonary toxicity\"]", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" \"PATHOLOGY\": [\"autoimunes diseases\"]\n\nThis is a Portuguese text, and the translation provided is an approximation. The original text may have referred to other specific diseases or conditions. The translation should be verified by a native Portuguese speaker or a professional translator.", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" \"PATHOLOGY\": [\"venlafaxina\"]\n\nThis text suggests that the accumulation of venlafaxine due to inhibition of CYP2D6 enzyme activity and the presence of a slow metabolizer phenotype may have resulted in toxic clinical manifestations.", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" \"PATHOLOGY\": []", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" I'm unable to parse this information as it is not in English and does not contain any identifiable pathologies or entities related to pharmacology.", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" \"PATHOLOGY\": []\n\nThis text is not about a specific pathology or disease. It is a description of a patient who was investigated for various possible causes and was 35 years old and previously hypoid.", {}]], [323, "Apoio financeiro: Nenhum.", [" This text does not provide any information related to pathologies or entities that need to be parsed for the given format.", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" {\"PATHOLOGY\": [\"menopausal symptoms\"]}", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" \"PATHOLOGY\": [\"menopause\", \"surgery\", \"chemotherapy\", \"hysterectomy\", \"endometrial hyperplasia\", \"endometrial cancer\", \"breast cancer\", \"sex hormone\u2013related cancers\", \"hypertension\", \"uncontrolled hypertension\", \"diabetes mellitus\", \"uncontrolled diabetes mellitus\", \"thromboembolism\", \"cerebrovascular disease\", \"cardiovascular disease\", \"atypical uterine bleeding\", \"sleep inducers\", \"antidepressants\", \"selective estrogen receptor modulators\", \"antihyperlipidemic drugs\", \"antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel)\", \"bisphosphonates\", \"calcitonin\", \"isoflavone\", \"flaxseed\", \"pomegranate\", \"horseradish\", \"white sorghum\", \"red shamrock\", \"red ginseng products\", \"functional foods and herbal medicines\", \"bone health\", \"blood lipid lipids (triglyceride and cholesterol)\", \"blood circulation\", \"female hormone formulations\", \"alanine aminotransferase (ALT)\", \"aspartate aminotransferase (AST)\", \"drug or alcohol abuse\", \"intensive exercises\", \"hypersensitivity to the test drug or its ingredients\", \"clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS))\"]", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" \"PATHOLOGY\": []", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" {}\n\n\"PATHOLOGY\": []\n\n(No new entities were identified in this statement)", {}]], [328, "p-value by Fisher's exact test.", [" \"STATISTICS\": [\"p-value\", \"Fisher's exact test\"]\n\nPlease note that \"PATHOLOGY\" field should only contain information related to diseases or side effects.", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" \"PATHOLOGY\": [\"pruritus\", \"hot flash\", \"headache\"]", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" \"PATHOLOGY\": []", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" {\"PATHOLOGY\": [\"menopausal subjects\"]}", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" \"PATHOLOGY\": []\n\nThis passage is not discussing any specific pathology or side effect. It is describing the results of a study on the inhibition of certain enzymes (UGT1A1 and UGT2B7) by celastrol using inhibition kinetic methods (Dixon plot and Lineweaver-Burk plot).", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" \"PATHOLOGY\": []", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" There is no clear mention of a specific pathology or disease in this statement. Therefore, there is no need to include it in the \"PATHOLOGY\" field.", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {}\n\"PATHOLOGY\": [],\n\"CHEMICALS\": [\"celastrol\"]\n}\n\nThe inhibition kinetic parameter (Ki) for celastrol is 0.49 \u03bcM.", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this sentence)", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" \"PATHOLOGY\": [\"clofibric acid\", \"valproic acid\"]", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" {\"PATHOLOGY\": []}\n\nThis information does not provide any specific pathology or disease mention.", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It is discussing the inhibition of an enzyme, UGT2B7, by the compound celastrol.", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" \"PATHOLOGY\": [\"diabetes\", \"chronic liver disease\"]", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" \"PATHOLOGY\": []", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathologies or side effects. It is discussing the use of valsartan as a model drug for investigating herb-drug interactions with RGE or ginsenosides.", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" \"PATHOLOGY\": []", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathologies or side effects. It only discusses the unbound fraction of tri-glycosylated PPD-type ginsenosides in rat plasma and liver.", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" \"PATHOLOGY\": []\n\n(This passage does not mention any specific pathology or side effect.)", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" {}\n\nThere is no mention of any pathology or side effects in this text.", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" \"PATHOLOGY\": []", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" \"PATHOLOGY\": []\n\nThis passage is discussing pharmacokinetic parameters in rats, not related to any specific disease or pathology.", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" \"PATHOLOGY\": []\n\nThis statement does not mention any specific pathology or side effect. It is a general statement about the need to assess herbal products for their interactions with other drugs.", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" No pathology or side effect mentioned in this text.", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" {}\n\nThere is no mention of a specific pathology or side effect in this text.", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" \"PATHOLOGY\": [\"PCOS\"]\n\n\"DISEASE OR DISORDER\": [\"polycystic ovary syndrome\"]\n\n\"BIOCHEMICAL PROCESS\": [\"oxidative stress\"]\n\n\"ENTITIES\": [\"catalase (CAT)\", \"glutathione peroxidase (GPx)\", \"superoxide dismutase (SOD)\", \"malondialdehyde (MDA)\"]", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" \"PATHOLOGY\": [\"PCOS\"]", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" \"PATHOLOGY\": [\"diabetes\", \"insulin\", \"blood glucose\"]", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" \"PATHOLOGY\": [\"OS\"] (Oxidative Stress)", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" \"PATHOLOGY\": [\"MDA\"]\n\n\"ANTIOXIDANTS\": [\"SOD\", \"CAT\"]\n\nNote: I assumed \"MDA\" stands for malondialdehyde, a marker for lipid peroxidation.", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" No specific pathologies or entities mentioned in this text.", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" No pathology or side effect was mentioned in this text.", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" No specific pathologies or side effects were mentioned in this text. Therefore, there is no need to include a \"PATHOLOGY\" field in the output.", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" {}\n\n\"PATHOLOGY\": []\n\nThis passage does not provide any information about a specific pathology or condition. It is only describing the study design and participant allocation.", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" \"PATHOLOGY\": []", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology or side effect mentioned in this context)", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" \"PATHOLOGY\": [\"MDA\", \"SOD\", \"CAT\", \"GPx\"]\n\nThese are markers of oxidative stress.", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" \"PATHOLOGY\": [\"diabetes\", \"FBS (Fasting Blood Sugar)\"]\n\nThis information suggests that ginger can help decrease the FBS level in people with diabetes by activating pancreatic \u03b2 cells to release insulin through the mechanism of serotonin receptors.", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" \"PATHOLOGY\": [\"diabetes\"]\n\nThis information suggests that spearmint phenolic phytochemicals have hypoglycemic (blood sugar lowering) and antioxidant properties, which may be relevant to diabetes.", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" \"PATHOLOGY\": [\"insulin tolerance\", \"glucose levels\"]}\n\nNote: \"hypolipidemic effects\" can also be considered a pathology, but it's often used to describe a therapeutic effect rather than a disease state. In this context, it's likely being used to describe the beneficial effect of PMFs on lipid levels.", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" It is not clear what specific pathologies or entities are being referred to in the statement \"All of this research is consistent with our study.\" Therefore, no information should be added to the \"PATHOLOGY\" field in this case.", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" \"PATHOLOGY\": [\"PCOS\"]\n\n\"SEXUAL\\_HORMONES\": []\n\n\"LIPID\\_PROFILE\": []", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" **\"PATHOLOGY\": [\"Polycystic ovary syndrome (PCOS)\"]**", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" \"PATHOLOGY\": []", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" \"PATHOLOGY\": [\"HIV\"]", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" No pathology or entity mentioned in this text.", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" \"PATHOLOGY\": [\"blood counts\", \"chemistry\", \"CD4+ T-cell count\", \"HIV-1 RNA load\"]", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" This passage does not provide any information about pathologies or side effects.", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" \"PATHOLOGY\": [\"CD4+ T-cell count\"]\n\nNote: No specific disease or condition was mentioned in this context, so it was assumed that \"cells/mm3\" refers to a measurement of the CD4+ T-cell count in the blood.", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" \"PATHOLOGY\": [\"HIV-1\"]\n\nNote: No new pathologies were mentioned in this text.", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" \"PATHOLOGY\": [\"\"]\n\n(Darunavir is a medication, therefore no pathology is mentioned in this context)", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" \"PATHOLOGY\": [\"darunavir\"]\n\n\"DRUG\": [\"E. purpurea\"]\n\n\"INTERACTION\": [\"coadministration\", \"little change\", \"C\u03c4\", \"AUC\u03c4\", \"decreasing\"]\n\nNote: The \"DRUG\" key is used to specify the interacting drug or herb. In this case, it is \"E. purpurea\".", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" \"PATHOLOGY\": [\"\"]\n\nThis information does not provide any mention of specific pathologies or side effects.", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" \"PATHOLOGY\": [\"antiretroviral agents\"]", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" \"PATHOLOGY\": [\"darunavir\"]", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" \"PATHOLOGY\": []", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" \"PATHOLOGY\": []", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" \"PATHOLOGY\": []", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" {}", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" I cannot determine any pathologies or side effects from this statement. It is a description of a method used in an analysis.", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" \"PATHOLOGY\": []", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" No pathology mentioned in this sentence.", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathology or side effect. It is discussing the dosage and induction of CYPs (Cytochrome P450 enzymes) by EGb 761\u00ae.", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" \"PATHOLOGY\": []", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" \"PATHOLOGY\": []", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" I cannot directly parse the PubMed search strategy as it is not provided in the text. However, I can provide an example of how the information might be formatted for the given context:\n\n{\"PATHOLOGY\": [], \"SEARCH\\_STRATEGY\": [\"(medicinal plants OR herbs OR extracts) AND (CYP2B6 OR cytochrome P450 2B6) AND (HIV OR human immunodeficiency virus)\"]}\n\nPlease note that this is just an example and the actual search strategy may vary.", {}]], [395, "Type of participant.", [" It is not possible to determine the type of participant from the given text.", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" No pathology mentioned in this text.", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" {}\n\n\"PATHOLOGY\": []\n\nThis sentence does not contain any specific pathology or side effect information. It is about the study selection and data extraction process.", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" I cannot directly provide the contents of Table 2 as I don't have access to the specific article you're referring to. However, based on the context, it seems that \"herbal preparations\" likely refer to various extracts or formulations derived from medicinal plants. Therefore, the following entities could potentially be found in Table 2:\n\n\"PATHOLOGY\": [],\n\"ENTITIES\": [\"herbal preparations\", \"extracts\", \"formulations\"]\n\nPlease note that without access to the actual table, I cannot guarantee the accuracy or completeness of the entities listed above.", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It only refers to \"incomplete outcome data\" and the reporting of \"attrition\" (i.e., participants dropping out of the study) in seven trials.", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" I'm unable to determine the relevance of this information to the cited entities in the text. It appears to be related to a study's assessment of risk of bias, but without additional context, it's unclear how it relates to the mentioned pathologies or entities. Therefore, I cannot include it in the output.\n\nThe output will only include the entities directly mentioned in the text.\n\n{\"PATHOLOGY\": [\"menopausal symptoms\", \"menopausal\", \"CKD\"]}", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" \"PATHOLOGY\": []\n\nThis information does not provide any details about specific pathologies or diseases. It is about the percentage of CONSORT (Consolidated Standards of Reporting Trials) statements that were followed in the reporting of clinical trials in the articles.", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" \"PATHOLOGY\": []", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology mentioned in this context)", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" \"PATHOLOGY\": [\"hepatic damage\"]\n\nThis entry indicates that the study reported that gingko did not cause hepatic damage.", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" \"PATHOLOGY\": []", {}]], [408, "(DOCX) Click here for additional data file.", [" I cannot click on links or access external files within this text-based environment. If there is important information in the attached document, please provide the details or data from the file within the text of the article.", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" \"PATHOLOGY\": [\"prothrombin time (PT)\", \"activated partial thromboplastin time (aPTT)\", \"international normalized ratio (INR)\"]", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" \"PATHOLOGY\": [\"coagulopathy of unknown origin\", \"warfarin or super-warfarin exposure\", \"disseminated intravascular coagulation (DIC)\", \"vitamin K malabsorption\"]", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" \"PATHOLOGY\": []", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" \"PATHOLOGY\": []", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" No pathologies or side effects mentioned in this text.", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" No pathologies or side effects were mentioned in this text.\n\nTherefore, the output should be an empty dictionary.\n\n{\"PATHOLOGY\": []}", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" \"PATHOLOGY\": [\"herb\u2013drug interactions\"]", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" \"PATHOLOGY\": [\"\"]\n\nNo specific pathologies or side effects were mentioned in this text.", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" \"PATHOLOGY\": []", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" \"\"PATHOLOGY\" : []\n\nThis statement does not mention any specific pathology or side effect. It is discussing the importance of conjugative metabolism in drug development.", {}]], [420, "Supporting Information Click here for additional data file.", [" I cannot access or parse information from external links or files. The information provided in the main text of the article should be sufficient for parsing the cited entities.", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" No pathology mentioned in this text.", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology or side effect mentioned in the text)", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" No specific pathology mentioned in this statement.", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" {\"PATHOLOGY\": []}\n\nThis information does not provide any specific pathology or side effect information. It only states the number and type of interactions for different categories.", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" \"PATHOLOGY\": [\"CBZ\"]\n\n\"DRUGS\": [\"CBZ\"]\n\n\"HERBAL\\_PRODUCTS\": []\n\n\"FOOD\": []", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" \"PATHOLOGY\": []", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" \"PATHOLOGY\": []\n\nThese citations do not provide information about specific pathologies or side effects. They refer to scientific publications and databases.", {}]], [428, "2012).", [" This information does not provide any reference to a pathology or entity. It is just the publication year.", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology or side effect mentioned in this text.)", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" \"PATHOLOGY\": [\"epilepsy\"]\n\n\"PATHOLOGY\": [\"rats\"]\n\n\"DRUG\": [\"CBZ\", \"folinic acid\", \"nicotinamide\"]", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" \"PATHOLOGY\": [\"epilepsy\"]", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" No pathology or side effect information was found in this text.", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" \"PATHOLOGY\": []", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" \"PATHOLOGY\": [\"CBZ\"]\n\n\"DRUG\": [\"Ispaghula husk\", \"septilin\", \"soybean\", \"Xiao-cha-hu-tang\"]", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" \"PATHOLOGY\": [\"alcohol\"]", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" \"PATHOLOGY\": [\"major depression\", \"bipolar disorder\", \"side effects\", \"dizziness\", \"blurred vision\", \"skin rash\", \"nausea\"]", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" \"PATHOLOGY\": []\n\nThis sentence does not refer to any specific pathology or side effect. It is about the composition of individual herbs in herbal formulae.", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" \"PATHOLOGY\": []\n\n(No specific pathology mentioned in the text)", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" \"\"PATHOLOGY\" : []", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" No pathology or entity mentioned in this statement.", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" I cannot directly parse the information from a table, but assuming the table contains information related to patient characteristics, the following pathologies can be inferred from the context:\n\n\"PATHOLOGY\": []\n\nIf new information is added to the table, please provide the table content for parsing.", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" \"PATHOLOGY\": [\"type-2 diabetes\"]", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" \"PATHOLOGY\": [\"patients\"]\n\nThis information does not provide enough detail to identify specific pathologies or side effects related to the prescribed hypoglycaemic agents. Therefore, the \"PATHOLOGY\" field should be left empty for this entry.", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" \"PATHOLOGY\": [\"diabetes\"]", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" \"PATHOLOGY\": [\"diabetes\"]", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It is discussing the importance of healthcare practitioners being aware of their patients' use of herbal medicines for interaction monitoring.", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" \"PATHOLOGY\": []", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" No pathology mentioned in the text.", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" \"PATHOLOGY\": [\"hepatocellular carcinoma\"]\n\n\"CELL LINE\": [\"HepaRG\"]", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" \"PATHOLOGY\": []", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" {}\n\n\"PATHOLOGY\": []\n\n(This section does not provide information about any specific pathology or side effect)", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" No pathology mentioned in this statement.", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" \"PATHOLOGY\": [\"liver\"]", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" No pathologies or side effects were mentioned in this text.", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" No pathology or entity was mentioned in this statement. Therefore, there is no need to include it in the output.", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" No pathology mentioned in the text.", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It refers to the mechanism of interaction between aspirin and a particular system (Peripheral Nervous System, PNS).", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" No pathology or side effect mentioned in this sentence.", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" {}\n\n\"PATHOLOGY\": []\n}\n\nThis information does not refer to any specific pathology or disease. It is a statistical notation indicating a significant difference from the control group.", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" \"PATHOLOGY\": []", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" \"PATHOLOGY\": []", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" \"PATHOLOGY\": []", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific diseases or conditions. It only discusses the inhibition of certain enzymes (CYP3A4 and CYP2C19) by specific plant extracts (Samento and Banderol).", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" \"PATHOLOGY\": [\"aryl hydrocarbon receptor (AhR)\"]\n\n\"CHEMICALS\": [\"omeprazole\"]", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" \"PATHOLOGY\": []", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" \"PATHOLOGY\": [\"drug efficacy\"]\n\n\"DRUGS\": [\"rifampicin\", \"St. John\u2019s Wort\"]\n\n\"ENTITIES\": [\"drug metabolizing enzymes\", \"drug transporters\"]", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" \"PATHOLOGY\": []", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" \"PATHOLOGY\": []", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" No pathology mentioned in this text.", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" No pathologies or side effects were mentioned in this text.", {}]], [471, "Data were evaluated as described previously [28].", [" Empty. No pathology or entity mentioned in the text.", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" \"PATHOLOGY\": []", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" \"PATHOLOGY\": []\n\nThis section does not contain any specific pathologies or side effects mentioned. It is a list of acknowledgments to individuals and institutions involved in the study.", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" This information does not refer to a specific pathology or entity. It is a statistical significance indicator.", {}]], [475, "Results of the reporter gene assays.", [" \"PATHOLOGY\": []", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" \"PATHOLOGY\": []\n\nExplanation: In this context, \"pregnane x receptor (PXR)\" is a protein and not a disease or pathology. Therefore, there is no need to include it in the \"PATHOLOGY\" field.", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" \"PATHOLOGY\": [\"\"]\n\n(No relevant pathology or side effect mentioned in the given text)", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" \"PATHOLOGY\": []", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in the given text.)", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" No pathology or side effect found in this statement.", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" \"PATHOLOGY\": []", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" \"PATHOLOGY\": []\n\nThis table lists the major ingredients of a specific suspension with their quantities. No specific diseases or pathologies are mentioned in this context.", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" \"PATHOLOGY\": []", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" \"PATHOLOGY\": []", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" No pathology or side effect mentioned in this text.", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" No pathology or side effect mentioned in this text.", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" No pathologies or side effects mentioned in this text.", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" No pathology mentioned in this text.", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" \"PATHOLOGY\": []", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" \"PATHOLOGY\": []\n\nThis part of the text is not discussing any specific pathology or side effect. It is about the study's findings on the inhibitory effects of \"woohwangcheongsimwon suspension\" on the pharmacokinetics of bupropion.", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" \"PATHOLOGY\": [\"statins\"]", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" \"PATHOLOGY\": [\"malignancies\"]", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" \"PATHOLOGY\": [\"Pgp/MDR1 protein\"]\n\n\"DRUG\": [\"APG\", \"DAS\"]\n\n\"PROTEIN\": [\"Pgp/MDR1 protein\"]\n\n\"UNIT\": [\"%\"]\n\n\"STATISTICS\": [\"significant inhibition\", \"p < 0.05\"]\n\n\"METHOD\": [\"treated rats\", \"compared to DAS alone\"]\n\n\"FINDING\": [\"65.38% and 69.90% inhibition\"]\n\n\"NOTES\": [\"This information is provided for context and additional details, but it does not need to be included in the final output as it is not a citation or a direct quote from the text.\"]\n\nOutput: {\"PATHOLOGY\": [\"Pgp/MDR1 protein\"]}", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" {\"PATHOLOGY\": []}\n\nThis passage does not mention any specific pathology or side effect. It is discussing the investigation of the inhibitory potential of APG on BCRP/ABCG2 protein expression.", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" \"PATHOLOGY\": [\"\"]\n\nNo specific pathology or side effect was mentioned in the provided text.", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" \"PATHOLOGY\": [\"drug-metabolizing enzymes\", \"drug transporters\"]\n\nAdditionally, it is important to note that the term \"herbs\" in this context refers to medicinal plants and their extracts.", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathologies or side effects. It only refers to the interaction between two drugs, APG and DAS.", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" It is not clear from the provided text what condition or pathology is being referred to with the abbreviation \"DAS\" or what \"radical alteration\" means in this context. Therefore, no information can be added for the \"PATHOLOGY\" field in this instance.", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" \"PATHOLOGY\": []\n\nThis passage does not contain any specific reference to a pathology or side effect. It is a description of an experimental setup for an animal study.", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" No pathologies or side effects mentioned in this text.", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" {}\n\n\"PATHOLOGY\": []\n\nThis passage does not contain any mention of a specific pathology or side effect. It is only describing the administration of APG (Aspergillus parasticolor) to different groups of animals and the timing of the administration.", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" No pathology or side effect mentioned in this text.", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" \"PATHOLOGY\": []", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" I'm unable to determine the meaning of \"M.A.A.\" in this context without additional information.", {}]], [507, "; supervision, K.M.A.", [" I cannot extract any pathology information from this text as it only mentions a person's name, K.M.A.", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" This statement is not related to pathologies or side effects. It is a statement about the authors' actions regarding the publication of the manuscript. Therefore, it should not be included in the output.", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" \"PATHOLOGY\": []", {}]], [510, "All results are presented as the average \u00b1 SD.", [" \"PATHOLOGY\": []", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" \"PATHOLOGY\": [\"rats\", \"hepatic\", \"intestinal\"]\n\n\"BCRP/ABCG2\": []\n\n\"protein expression\": []\n\n\"after DAS administration\": []\n\n\"with or without APG pretreatment\": []", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" \"PATHOLOGY\": []\n\nThis statement does not directly refer to any specific pathology or disease. It is discussing the potential interaction between phytochemicals and cytochrome P-450 enzymes.", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" \"PATHOLOGY\": [\"HIV\"]\n\nThis population refers to individuals with HIV.", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" \"PATHOLOGY\": [\"elders\"]\n\nThis information does not provide any specific pathology or side effect related to the ingestion of botanical supplements with prescription medications.", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" {\"PATHOLOGY\": [\"\"]}\n\n(Note: No specific pathology or side effect was mentioned in the text.)", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {\"PATHOLOGY\": [\"\"]}\n\nThis line does not provide enough information to determine the specific pathologies or entities involved in the interaction.", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {}\n\"PATHOLOGY\": []\n}\n\nThis hypothesis does not refer to any specific pathology or side effect.", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" No pathologies or side effects were mentioned in this text.", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" No pathology mentioned in the text.", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" No pathology mentioned in the text.\n\n{\"PATHOLOGY\": []}", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" No pathologies or side effects were mentioned in this text.", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" \"PATHOLOGY\": []", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" {}\n\n\"PATHOLOGY\": []\n\n(This section does not provide any new information about pathologies or side effects)", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" \"PATHOLOGY\": [\"reduced oxidative metabolism\"]", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific diseases or pathologies. It only discusses St. John's wort and its interactions with other drugs.", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" \"PATHOLOGY\": []", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" \"PATHOLOGY\": []", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" \"PATHOLOGY\": [\"depression\"]", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" \"PATHOLOGY\": [\"depression\"]", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" \"PATHOLOGY\": []", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" \"PATHOLOGY\": []\n\nThis passage is discussing the interaction between hyperforin and OATP2B1, a transporter protein. No specific diseases or pathologies are mentioned in this context.", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" \"PATHOLOGY\": []", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" \"PATHOLOGY\": [\"cancer\"]", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" \"PATHOLOGY\": [\"cancer\"]", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" \"PATHOLOGY\": []\n\nThis statement does not mention any specific pathology or disease. It is discussing the use of medicinal mushrooms in the study design.", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {}\n\nThis line is an empty object, it does not contain any information related to pathologies or entities.", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" \"PATHOLOGY\": [\"cancer\", \"immunosuppression\"]\n\n\"DISEASE\": [\"opportunistic infections\", \"HIV\"]\n\n\"CELLS\": [\"T cells\", \"Bax\", \"phagocytic activity\", \"antibody production\", \"delayed hypersensitivity\", \"WBC\", \"platelets\", \"bone marrow cells\"]\n\n\"DRUGS\": [\"5-FU\", \"cytotoxic drugs\"]\n\n\"PROTEINS\": [\"CYP2B6\", \"Caspase 3\"]\n\n\"PHENOMENA\": [\"apoptosis\", \"cell cycle arrest\", \"immunosuppression\", \"tumor inhibition\", \"metastasis\"]", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" \"PATHOLOGY\": [\"tumor recurrence\", \"metastasis\"]", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" \"PATHOLOGY\": [\"tumor\", \"tumor cell\"]", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" \"PATHOLOGY\": [\"tumor metabolism\"]\n\n\"DISEASE OR CONDITION\": [\"paclitaxel-induced gut dysbiosis\"]", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" \"PATHOLOGY\": [\"cancer\"]", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" I'm unable to understand the context of the letter \"a\" in this sentence. It's likely a typo or an error. Without more information, it's impossible to determine if it refers to any specific entity or pathology. Therefore, I cannot include it in the output.", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" \"PATHOLOGY\": [\"T helper cells\", \"apoptosis\"]\n\n\"IMMUNE SYSTEM\": [\"T-bet\", \"GATA-3\", \"Bax\", \"Foxp3\", \"PD-1\"]", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" \"PATHOLOGY\": []", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" It is unclear what Table S4 refers to without additional context. Therefore, it cannot be parsed for pathologies or entities.", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" I'm an AI language model and don't have the ability to conduct research or be accountable for the accuracy or integrity of any scientific work. This statement is for human researchers to agree upon in order to ensure the validity and reliability of their study.\n\n\"PATHOLOGY\": [] (Since this statement doesn't mention any specific pathologies or diseases)", {}]], [547, "Not applicable.", [" {}\n\nThis statement indicates that the information provided in the text does not contain any references to pathologies or side effects.", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" \"PATHOLOGY\": [\"breast cancer\"]", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" \"PATHOLOGY\": [\"breast tumors\", \"early stage breast cancer\", \"metastatic breast cancer\", \"hormone receptor positive breast cancer\"]", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" \"PATHOLOGY\": [\"breast cancer\", \"other types of cancer\"]", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathology or side effect. It only provides information about the medicinal product (VAEM, Iscador Qu spec) and its composition (host tree Malus domestica, total mistletoe lectin concentration 306 ng/mL).", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" No pathologies mentioned in this text.", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" 1).{\"PATHOLOGY\": []}\n\nThis text does not mention any specific pathology or side effect. It is discussing the results of a study and the significance of those results in relation to VAEM (Vaginal Aqueous Endometrial Mucus) and endoxifen.", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" \"PATHOLOGY\": [\"patients\"]\n\nThis statement does not provide enough context to determine if there is a specific pathology or condition being referred to. However, it mentions that the information comes from studies on genotype combinations and enzyme phenotypes, so it may be related to pharmacogenetics or drug metabolism.", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" \"PATHOLOGY\": [\"breast cancer\"]", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" \"PATHOLOGY\": [\"genetic polymorphisms\"]", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" I cannot extract information from a figure as it does not contain text. Figure S2 is likely a supplementary figure to the article.", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" This statement is not related to pathologies or side effects. It is a disclaimer from the publisher.", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" \"PATHOLOGY\": []", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" No pathologies or side effects mentioned in this text.", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" No pathologies or side effects mentioned in this text.", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" \"PATHOLOGY\": []", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" No pathology mentioned in this text.", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" \"PATHOLOGY\": []", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" No pathology mentioned in the text.", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" No pathology mentioned in the text.", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" No pathology mentioned in this text.", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" No pathology or side effect was mentioned in this sentence.", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" {\"PATHOLOGY\": [\"\"]}\n\n(No specific pathology or side effect was mentioned in this sentence.)", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" \"PATHOLOGY\": []", {}]], [572, "2016).", [" This information does not provide any reference to a pathology or entity. It is just the publication year.", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" No pathologies or side effects were mentioned in this text.", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" No pathology mentioned in the text.", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" No pathology mentioned in this text.", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {\"PATHOLOGY\": []}\n\nThis passage does not mention any specific diseases or conditions. It only discusses the interaction between two drugs (GLT and AC).", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" Understanding the interactions between medicinal plants and drugs used in clinical settings is essential for optimizing patient care and minimizing potential adverse effects. The findings from this study on the inhibition of CYP2B6 enzyme activity by selected medicinal plant extracts used by HIV patients could have significant implications for clinical pharmacology and translational science.\n\nFirst, healthcare professionals can use this information to make informed decisions about drug-herb interactions and potential risks for patients. By being aware of these interactions, clinicians can adjust dosages, monitor for adverse effects, and consider alternative treatment options to minimize potential harm.\n\nSecond, this study highlights the importance of conducting thorough pharmacokinetic and pharmacodynamic studies to evaluate the potential interactions between medicinal plants and prescription drugs. This knowledge can help inform the development of evidence-based guidelines for the use of herbal medicines in clinical settings.\n\nThird, translational science can benefit from this research by providing insights into the mechanisms of drug-herb interactions and shedding light on potential therapeutic targets. This information can inform the design of future studies and clinical trials, ultimately leading to improved patient outcomes and more effective treatments.\n\nOverall, the findings from this study have the potential to change clinical pharmacology and translational science by improving our understanding of drug-herb interactions and informing evidence-based decision-making in patient care.", {}]], [578, "(n\u00a0=\u00a06).", [" This information does not provide any details about a pathology or entity. It is likely a reference to the number of participants in a study. Therefore, it should not be included in the \"PATHOLOGY\" field.", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" I'm an AI language model and I don't have the ability to write manuscripts or parse scientific articles directly. However, based on the provided text, I can identify the following pathologies mentioned:\n\n{\"PATHOLOGY\": [\"menopausal symptoms\", \"menopausal\", \"CKD\", \"HIV\", \"HIV-associated opportunistic infections\", \"type 2 diabetes\", \"hypertension\"]}", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" No pathology or entity information was provided in the given text.", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" No pathology or entity information was provided in the given text.", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" \"PATHOLOGY\": [\"diabetes mellitus\"]", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" \"PATHOLOGY\": [\"blood glucose level\"]", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" \"PATHOLOGY\": [\"diabetes\"]\n\n\"BIOACTIVE CONSTITUENTS\": [\"anthocyanins\", \"flavonoids\"]\n\n\"DRUGS\": [\"Gliptins\"]", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" \"PATHOLOGY\": [\"diabetes\"]", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" No pathology mentioned in this text.", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" No pathologies or side effects mentioned in this text.", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" No pathologies or side effects were mentioned in this text.\n\nTherefore, the output will be an empty dictionary.\n\n{\"PATHOLOGY\": []}", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" \"PATHOLOGY\": [\"glucose level\"]", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" I apologize for the lack of context in the provided information. Without additional information, it is not possible to determine the entities referred to in \"3a and b\". Please provide more context for an accurate parsing of entities.", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" \"PATHOLOGY\": []\n\nThis information does not refer to any specific pathology or side effect. It is about mass chromatograms of SITA and PRM.", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" \"PATHOLOGY\": [\"diabetes\", \"liver damage\"]", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" No pathology mentioned in this text.", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" This information does not provide any specific pathology or entity. It is a statistical description indicating a significant difference between groups.", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" 1) and serum creatinine (Fig. 2) in rats with CKD compared to the control group.\n\n\"PATHOLOGY\": [\"CKD\", \"elevated levels of BUN\", \"elevated levels of serum creatinine\"]", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" I cannot determine any pathologies or entities from the given information as it only refers to a table number in the text.", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" This information does not provide any specific pathology or entity. It is a statistical description indicating a significant difference between groups.", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It is only reporting the results of a study on the interaction between indomethacin and A. officinarum.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" \"PATHOLOGY\": []\n\nThis information does not provide any specific pathology or side effect information. It is only mentioning that A. Officinarum accelerates the excretions of indomethacin and its metabolites.", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" No pathology mentioned in the text.\n\n{\"PATHOLOGY\": []}", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" {}\n\"PATHOLOGY\": []\n}\n\nThis passage does not mention any specific pathology or disease.", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" {}\n\nThere is no mention of a specific pathology or side effect in this text.", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" {}\n\nThis text does not provide any information about pathologies or side effects.", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" \"PATHOLOGY\": []", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" \"PATHOLOGY\": [\"gastric injury\"]", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" {}\n\"PATHOLOGY\": []\n\nThis passage does not mention any specific pathology or side effect. It only refers to the plasma concentration-time curves of indomethacin in different groups.", {}]], [607, "1).", [" I'm assuming you're asking for the first entry in the list of citations. Here it is:\n\n{\"PATHOLOGY\": []}\n\nThis entry refers to the context of the text before the first citation, where no specific pathology or entity is mentioned.", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" \"PATHOLOGY\": [\"therapeutic INR\"]\n\n\"DISEASE\": [\"maintenance daily dose of warfarin\"]\n\n\"MEDICATION\": [\"warfarin\"]", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" \"PATHOLOGY\": [\"anticoagulant therapy\"]", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" \"PATHOLOGY\": []", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" \"PATHOLOGY\": [\"atrial fibrillation\"]", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" \"PATHOLOGY\": [\"prosthetic heart values\"]", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" {}\n\nThere is no need for a \"PATHOLOGY\" field in this case as there is no mention of any specific pathologies or side effects in the given text regarding the conflict of interests statement.", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" \"PATHOLOGY\": []", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" \"PATHOLOGY\": [\"blood pressure\"]", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" \"PATHOLOGY\": [\"hypertension\"]\n\n\"ENTITY\": [\n\"anthocyanins\",\n\"delphinidin-3-sambubioside\",\n\"cyanidin-3-sambubioside\",\n\"HS\"\n]", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" It is unclear what information is being referred to with \"7.2.\" as there is no context provided in the text. Therefore, there is no information to parse for pathologies or entities.", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" \"PATHOLOGY\": [\"cholesterol\", \"total cholesterol\", \"HDL-C\", \"LDL-C\", \"triglycerides\"]", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" \"PATHOLOGY\": [\"hypertensive patients\", \"total cholesterol\"]", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" \"PATHOLOGY\": []", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" \"PATHOLOGY\": [\"hypertension\"]\n\n\"MECHANISM\": [\"vasodilation\", \"endothelium-derived relaxant pathways\", \"inhibition of calcium influx\", \"ACE inhibition\", \"new vessel formation\", \"reduction of myocardial mass\", \"anthocyanins\", \"substrate\", \"active site\", \"cyclooxygenase inhibitory activity\", \"PI3-K/Akt\", \"ERK pathway\", \"adipocyte differentiation\"]", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" \"PATHOLOGY\": [\"liver\", \"kidney\"]", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" \"PATHOLOGY\": []", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" {}\n\n\"PATHOLOGY\": []\n\nThis statement does not provide any information about a specific pathology or condition. It is a statement about the manuscript and the service being provided by the publisher.", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" \"PATHOLOGY\": [\"imatinib\"]\n\nThis statement does not provide any additional information about a disease or condition, so the \"PATHOLOGY\" field is left empty.", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" \"PATHOLOGY\": []\n\n(This passage does not mention any specific pathology or side effect)", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" \"PATHOLOGY\": []\n\n\"KEYWORDS\": [\"drug metabolism\", \"herb\u2013drug interactions\", \"modelling and simulation\", \"physiologically-based pharmacokinetic (PBPK)\"]", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" \"PATHOLOGY\": []", {}]], [631, "Go to: 2.", [" I assume you mean the second paragraph of the text. Here's the parsed information:\n\n{\"PATHOLOGY\": [\"menopausal symptoms\", \"menopausal\"]}\n\nThis paragraph states that red ginseng is used to alleviate menopausal symptoms due to hormonal imbalance during menopause.", {}]], [632, "2.1.2.", [" I cannot provide an answer without additional context from the article. The number \"2.1.2\" appears to be a section heading or subheading within the article, and I would need the text within that section to determine any mentioned pathologies or entities.", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" \"PATHOLOGY\": []", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" No pathologies or side effects mentioned in this text.", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" No pathologies or side effects were mentioned in this text.\n\nTherefore, the \"PATHOLOGY\" field should be left empty.", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" No specific pathology mentioned in this text.", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" \"PATHOLOGY\": []", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" \"PATHOLOGY\": []", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" I cannot determine any pathologies or side effects from this statement.", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It is discussing the use of PBPK simulations to evaluate the interactions between Schisandra lignans and midazolam and tacrolimus.", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or identify entities from an external file. The information provided in the text should be sufficient for entity identification.", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" It is not clear what \"MBI\" stands for in this context without additional information. Therefore, there is no entity to parse for this term.\n\n\"mechanism-based inhibition\" can be parsed as:\n\n{\"PATHOLOGY\": []}\n{\"PROCESS\": [\"mechanism-based inhibition\"]}", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" \"PATHOLOGY\": [\"Schisandra lignans\"]\n\nThis information does not mention any specific chronic diseases or conditions. Therefore, no additional pathologies need to be added to the list.", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" \"PATHOLOGY\": []", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" \"PATHOLOGY\": [\"cancer\"]", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" \"PATHOLOGY\": [\"haemorrhage\"]\n\n\"DRUG\": [\"Ginkgo biloba\"]\n\n\"INTERACTION\": [\"antiplatelet agents\"]", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" \"PATHOLOGY\": [\"rats\"]", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathologies or side effects. It only describes the methods used in the study.", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It refers to the analysis of the effects of Danshen/Gegen on VKOR and TM for pharmacodynamic analysis.", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" \"PATHOLOGY\": []", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" No pathologies or side effects were mentioned in this text.", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" No pathologies or side effects were mentioned in this text.", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" \"PATHOLOGY\": []\n\nThis information does not provide any mention of a specific pathology or side effect. It is only reporting the results of a study regarding the expression ratio of CYP2C6.", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" \"PATHOLOGY\": []", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" This information does not provide any pathology or entity. It is a statistical significance indicator.", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" \"PATHOLOGY\": [\"microcirculation\", \"platelet aggregation\"]\n\n\"DRUG\": [\"warfarin\"]\n\n\"BIOCHEMICAL PROCESS\": [\"VKOR\", \"TM\"]\n\nNote: The \"DRUG\" field is only included for the specific drug mentioned, not for the medicinal plants.", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" \"PATHOLOGY\": [\"rats\"]\n\nThis information does not provide any details about human diseases or conditions.", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" \"PATHOLOGY\": []", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" \"PATHOLOGY\": [\"warfarin\"]\n\n\"DRUG\": [\"Gegen\", \"Danshen\"]", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" \"PATHOLOGY\": []\n\n(Note: CYP enzymes are not considered a disease or pathology, but rather a group of enzymes. Therefore, no entities were found in this text.)", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" \"PATHOLOGY\": []", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in the text.)", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" \"PATHOLOGY\": []\n\n(This passage does not mention any specific pathology or side effect.)", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" \"PATHOLOGY\": []", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" \"PATHOLOGY\": [\"liver\"]\n\n\"ENTITIES\": [\n\"cytochrome P450\",\n\"vitamin K epoxide reductase\",\n\"vitamin K\",\n\"thrombomodulin\",\n\"Danshen\u2013Gegen Formula\",\n\"salvianolic acid B\",\n\"phenobarbital\",\n\"beta-napthoflavone\",\n\"cyclophosphamide\",\n\"enzyme-linked immunosorbent assay\",\n\"Beikang Ge\",\n\"Zhen Zhang\",\n\"BKG\",\n\"ZZh\",\n\"ZZu\"\n]", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" \"PATHOLOGY\": [\"early stage breast cancer\"]", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" \"PATHOLOGY\": []\n\nThis sentence does not provide any information about a specific pathology or condition. It only refers to a publication by Beer et al.", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" \"PATHOLOGY\": []", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" No pathology mentioned in the text.", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" \"PATHOLOGY\": []", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" \"PATHOLOGY\": []", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" \"PATHOLOGY\": [\"diabetes\", \"hypertension\", \"hyperlipidemia\", \"malaria fever\"]\n\n\"DISEASES AND CONDITIONS\": [\"terminal diseases\", \"chronically ill patients\"]\n\n\"ENTITIES\": [\"conventional medications\", \"alternative remedies\", \"dietary supplements\", \"herbal medicines\"]", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" \"PATHOLOGY\": [\"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\"]", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" \"PATHOLOGY\": []\n\nThis statement does not directly refer to any specific pathology or disease. It is discussing the role of CYP isoenzymes in metabolizing medications.", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" \"PATHOLOGY\": []", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" No pathology mentioned in this text.", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" No pathologies or side effects were mentioned in this text.", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" No new pathologies or entities were mentioned in this text. Therefore, the \"PATHOLOGY\" field remains empty.", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" This information does not refer to a specific pathology or entity. It is a method used in mass spectrometry analysis. Therefore, it should not be included in the \"PATHOLOGY\" field.", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" This information does not provide any reference to a specific pathology or entity. It is a description of a scientific term used in the study.", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" \"PATHOLOGY\": []", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" \"PATHOLOGY\": []", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" \"PATHOLOGY\": []", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" \"PATHOLOGY\": []", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" \"PATHOLOGY\": [\"\"]\n\n(Moringa oleifera is a plant, it is not considered a disease or pathology)", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" \"PATHOLOGY\": []", {}]], [689, "(2000).", [" It is unclear what \"2000\" refers to in this context, and it does not appear to be a pathology or entity. Therefore, it should not be included in the output.", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" \"PATHOLOGY\": [\"\"]\n\nThis passage does not directly mention any specific pathology or disease. The text is discussing the difficulty in identifying or quantifying the inhibiting components of complex mixtures of phytochemicals in herbs when studying herb-drug interactions.", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" \"PATHOLOGY\": [\"menopause\"]", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" \"PATHOLOGY\": [\"menopause\", \"hot flashes\", \"night sweats\", \"sleep disturbances\", \"sexual dysfunction\", \"mood disorders\", \"weight gain\", \"cognitive declines\"]", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" This text does not contain any mention of a pathology or side effect.", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" It is not clear from the provided text what pathology or entities are being referred to in this context. Therefore, no information can be added to the \"PATHOLOGY\" field.", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" \"PATHOLOGY\": [\"cardiovascular disease\", \"pulmonary disease\", \"hepatic disease\", \"renal disease\", \"hematologic disease\", \"gastrointestinal disease\", \"endocrine disease\", \"immunologic disease\", \"dermatologic disease\", \"neurologic disease\"]", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" \"PATHOLOGY\": [\"pregnancy\"]\n\n\"PATHOLOGY\": [\"breastfeeding\"]\n\n\"PATHOLOGY\": [\"planning to conceive a child\"]", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" \"PATHOLOGY\": []", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" No pathology mentioned in this text.", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" No pathologies or side effects were mentioned in this text.\n\nTherefore, the output will be an empty dictionary.\n\n{\"PATHOLOGY\": []}", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" No pathology or entity mentioned in this statement.", {}]], [701, "A difference was considered significant at P < 0.05.", [" No pathology or entity mentioned in this statement.", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" No pathology mentioned in this text.", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" \"PATHOLOGY\": []", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" \"PATHOLOGY\": [\"ischemic heart disease\", \"hypertension\", \"diabetes\"]", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" \"PATHOLOGY\": [\"drug interactions\"]", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" \"PATHOLOGY\": []", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" \"PATHOLOGY\": []\n\nThis information does not provide any specific pathology or disease mention. It only refers to a figure and its title, which does not contain enough information to determine any specific pathology or disease.", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" \"PATHOLOGY\": [\"CYP2C9\"]\n\n\"GENETIC VARIANTS\": [\"CYP2C9\\*1,\\*2 and \\*3\"]\n\n\"TECHNIQUE\": [\"PCR-RFLP analysis\"]\n\n\"PROTEIN\": [\"CYP2C9\"]\n\n\"GENE\": [\"CYP2C9\"]\n\n\"ANALYSIS\": [\"genotyping\"]\n\n\"METHOD\": [\"PCR-based\"]\n\n\"TECHNIQUE_DETAIL\": [\"restriction fragment length polymorphism (RFLP) analysis\"]\n\n\"APPLICATION\": [\"detection of genetic variants\"]\n\n\"SUBJECT\": [\"HIV patients\"]\n\n\"DISEASE\": [\"HIV\"]\n\n\"INFECTION\": [\"opportunistic infections\"]\n\n\"DRUG\": [\"antidiabetic drugs\"]\n\n\"HERB\": [\"medicinal plant extracts\"]\n\n\"GOAL\": [\"evaluation of inhibition of CYP2B6 enzyme activity\"]\n\n\"STUDY_TYPE\": [\"study\"]\n\n\"RESEARCH_AREA\": [\"pharmacology\"]\n\n\"RESEARCH_TOPIC\": [\"drug-herb interactions\", \"CYP2C9 genotyping\"]\n\n\"REFERENCE\": [\"[15]\"]\n\n\"NOTES\": [\"This information is based on the provided context and may not be exhaustive or completely accurate. It is recommended to consult the original article for more detailed and accurate information.\"]", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" \"PATHOLOGY\": []", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" \"PATHOLOGY\": [\"\"]\n\nThis table is reporting platelet aggregation results after 2 weeks of treatment with echinacea and policosanol. No specific pathologies or diseases are mentioned in this context.", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" \"PATHOLOGY\": []", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" \"PATHOLOGY\": [\"warfarin\"]", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" \"PATHOLOGY\": []\n\nThis information does not provide enough context to determine any associated pathologies or side effects.", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" \"PATHOLOGY\": []", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" \"PATHOLOGY\": [\"cancer\"]\n\n\"PATHOLOGY (disease or condition)\": [\"opportunistic infections\"]\n\n\"PATHOLOGY (population)\": [\"HIV patients\"]", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathologies or side effects related to the mentioned plants.", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" \"PATHOLOGY\": []", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" \"PATHOLOGY\": []", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" No pathologies or side effects were mentioned in this text.", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" No pathologies or side effects mentioned in this text.", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" No pathologies or side effects were mentioned in this statement. Therefore, the \"PATHOLOGY\" field should be left empty.", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" No pathologies or side effects were mentioned in this text.", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" It is unclear what information is associated with this number in the text. Therefore, no entities can be identified from this part of the text.", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" No pathologies or side effects mentioned in this text.", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It only refers to the structure of phytochemicals found in the aqueous extract of H. verticillata.", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" \"PATHOLOGY\": []", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" It is unclear from the provided context what \"Worse than the Disease?\" refers to in terms of pathologies or entities. Therefore, no information should be added to the \"PATHOLOGY\" field for this statement.", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or identify entities from an external file. The information provided in the text should be sufficient for entity identification.", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" No pathology mentioned in the text.", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" \"PATHOLOGY\": [\"rashes\"]", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" \"PATHOLOGY\": [\"rash\"]", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" \"PATHOLOGY\": [\"OS\"] (Oxidative Stress)", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathology or side effect. It only describes the source and identification details of a Radix Scutellariae extract used in the study.", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" \"PATHOLOGY\": []", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" No pathologies or side effects were mentioned in this text.\n\nTherefore, the \"PATHOLOGY\" field should be left empty.", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" No pathologies or side effects were mentioned in this text.\n\nTherefore, the output will be an empty dictionary.\n\n{\"PATHOLOGY\": []}", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" \"PATHOLOGY\": []", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" \"PATHOLOGY\": [\"rat\"]\n\n\"SPECIES\": [\"rat\"]\n\n\"SUBSTANCE\": [\"OS\"]\n\n\"SOLVENT\": [\"rat plasma\"]\n\n\"METHOD\": [\"incubation system\"]\n\n\"FUNCTION\": [\"discrimination\"]\n\n\"RESULT\": [\"no discrimination\"]\n\n\"CONDITION\": [\"super-fast reaction rate\"]\n\n\"ENTITY\": [\"studied herb/herbal components\"]\n\n\"CONTEXT\": [\"rat plasma contains 1 \u03bcg/mL of OS and 10% rat plasma\"]\n\nNote: This information is not directly related to the pathology, but it is important contextual information for understanding the experiment.", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" \"PATHOLOGY\": [\"OSA\"] (Obstructive Sleep Apnea)", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" 1 and 2), with the highest levels of degradation observed for the markers with the lowest molecular weights (i.e., MW) and the lowest levels for the markers with the highest MW.\n\n\"PATHOLOGY\": [] (No specific pathologies mentioned in this text)", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" \"PATHOLOGY\": [\"influenza\"]\n\n\"DISEASE INTERACTION\": [\"herb-drug interaction\", \"drug-drug interaction\"]\n\n\"PROCESS\": [\"absorption\", \"metabolism\"]", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" ].{\"PATHOLOGY\": []}This part of the text does not provide information about any specific pathology or side effect. It is discussing the results of a study regarding the interaction between two substances (RS and OS/OSA) and their systemic exposure.", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" 1).{\"PATHOLOGY\": []}\n\nThis statement does not mention any specific pathology or side effect. It is only referring to a finding in a rat study.", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" I'm unable to determine the meaning or context of \"S8\" without additional information. It could potentially refer to a specific reference or a subsection of the text. To accurately parse entities, it's important to have the full context.", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" \"PATHOLOGY\": [\"influenza viruses\"]\n\n\"PATHOLOGY\": [] (for other entities, no information was provided in the given text)", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific diseases or side effects related to pathologies.", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" \"PATHOLOGY\": []", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" \"PATHOLOGY\": [\"OS\"] (OS stands for overall survival)", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" \"PATHOLOGY\": []\n\nThis passage does not contain any specific references to pathologies or side effects. It is discussing the interaction between two compounds, RS and OS, and the impact of RS on the pharmacokinetics of OS.", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" \"PATHOLOGY\": [\"Root of Isatis indigotica\"]\n\nOr, if you prefer to keep it more specific:\n\n\"PATHOLOGY\": [\"Radix Isatidis\", \"Isatis indigotica\"]", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" \"PATHOLOGY\": [\"Fructus Arctii\", \"Arctium lappa L.\", \"Niubangzi\"]", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" \"PATHOLOGY\": [\"clinical breast cancer\"]", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" \"PATHOLOGY\": [\"TAM\"]", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" \"PATHOLOGY\": [\"breast cancer\"]", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" {\"PATHOLOGY\": []}\n\nThis passage does not mention any specific pathologies or side effects. It only lists the medicinal plants used in the study.", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathologies or side effects related to the entities mentioned.", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" \"PATHOLOGY\": [\"cancer\"]\n\n\"MECHANISM\": [\"apoptosis\", \"autophagy\", \"cell cycle arrest\"]", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" \"PATHOLOGY\": [\"MCF7\", \"T47D\"]\n\nThese entities are likely to be cell lines used in the study.", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" \"PATHOLOGY\": [\"MCF-7\", \"T-47D\"]\n\nThese entities are likely to be cell lines used in a study.", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" \"PATHOLOGY\": []", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" \"PATHOLOGY\": [\"MCF-7 tam-R\", \"TAM-resistant cells\"]\n\n\"ENTITY\": [\n\"Vitex negundo L.\",\n\"TAM\",\n\"apoptosis\"\n]", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" {\"PATHOLOGY\": []}", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" \"PATHOLOGY\": []", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" {}\n\"PATHOLOGY\": []\n\nThis statement does not provide any information about a specific pathology or condition. It refers to the protective effect being dose-dependent, but it is not clear what is being protected against.", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" \"PATHOLOGY\": [\"liver injury\", \"TAM-intoxicated\"]\n\n\"BIOCHEMICAL PROCESS\": [\"oxidative stress status\"]\n\n\"ENTITY\": [\"DDB\"]\n\n\"OUTCOME\": [\"significant increase in antioxidant enzymes\", \"significant decrease in the activity of sGPT and sGOT\", \"reduction of glutathione concomitant\", \"significant reduction of TBARS and liver transaminases\"]", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" \"PATHOLOGY\": []", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" \"PATHOLOGY\": [\"\"]\n\nThis passage does not provide any clear information about specific pathologies or side effects. It is discussing the inhibitory and inductive effects of GA and PCA on certain transporters (OAT1/3, MDR1, and BCRP).", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" \"PATHOLOGY\": [\"communicable diseases\"]", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" \"PATHOLOGY\": [\"urinary tract infections\", \"pyelonephritis\", \"prostatitis\"]", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" \"PATHOLOGY\": []", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" \"PATHOLOGY\": []\n\n(No specific pathology mentioned in the text)", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathologies or side effects were mentioned in this text.)", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" No pathologies or side effects were mentioned in the provided text.", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" No pathologies or side effects were mentioned in this text.\n\nTherefore, the output will be an empty dictionary.\n\n{\"PATHOLOGY\": []}", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" No pathology or side effect mentioned in this text.", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" I cannot directly parse the entities from this sentence as it does not explicitly mention any specific pathologies or diseases. However, based on the context, it appears to be discussing pharmacokinetic interactions between certain drugs (CIP, PCE, GA, and PCA). Therefore, I would leave the \"PATHOLOGY\" field empty for this sentence.", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" \"PATHOLOGY\": []\n\nThis passage is discussing pharmacokinetics and does not mention any specific diseases or conditions.", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" \"PATHOLOGY\": []\n\nThis passage is not discussing any specific pathology or side effect. It is about the effect of CIP on the tissue distribution of gallic acid and PCA.", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in the text.)", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" \"PATHOLOGY\": []", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" \"PATHOLOGY\": []", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" No pathology or entity mentioned in this statement.", {}]], [785, "Click here for additional data file.", [" I cannot follow the link or access external data files without additional information. Please provide the necessary context or a local file path for the data.", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" No pathologies or side effects were mentioned in this text.", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" No pathology or side effect mentioned in this text.", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" \"PATHOLOGY\": []\n\nThis information does not provide any reference to a specific pathology or side effect. It is discussing the difference in the total area under the curve (AUC) for a certain drug (CHO) between two groups (YM and PLC).", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" {}\n\"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It is only reporting the results of a study regarding Total Energy Expenditure (TEE) and its relationship to treatment and exercise time.", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" No specific pathology mentioned in this text.", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" \"PATHOLOGY\": [\"obese participants\"]\n\n\"PATHOLOGY\": [\"healthy\"]\n\n\"PATHOLOGY\": [\"metabolic rate\", \"RER\"]\n\n\"PATHOLOGY\": [\"blood lipid metabolites\"]", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" \"PATHOLOGY\": [\"\"]\n\nThis passage does not mention any specific pathologies or side effects. It is discussing the metabolic effects of certain compounds.", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" \"PATHOLOGY\": []", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" \"PATHOLOGY\": []", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" \"PATHOLOGY\": [\"\"]\n\nExplanation: The text does not mention any specific pathology or side effect in this section.", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" No pathology or side effect information was found in this statement.", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" No pathologies or side effects were mentioned in this text.", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this text.)", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" No pathology or entity mentioned in this statement.", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" \"PATHOLOGY\": []", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" No pathology or side effect mentioned in this text.", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" \"PATHOLOGY\": []\n\n(This passage does not mention any specific pathology or disease)", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" \"PATHOLOGY\": [\"\"]\n\nExplanation: In this context, \"HDI\" refers to \"drug-drug interactions\" or \"herb-drug interactions,\" so no specific pathology or side effect is mentioned in the text.", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" \"PATHOLOGY\": []\n\nThese mentioned entities are plants or herbs.", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or disease was mentioned in this context.)", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathology or side effect. It only discusses the importance of further studies related to HDIs (herb-drug interactions).", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" \"PATHOLOGY\": [\"cognition decline and memory loss\", \"anxiety and mood disorders\", \"fatigue\", \"cardiovascular disorders\"]", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" \"PATHOLOGY\": [\"seizure\", \"death\"]\n\nNote: It's important to mention that the information provided in this text is for the purpose of parsing the cited entities and does not imply any causal relationship between the mentioned conditions and the entities.", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" \"PATHOLOGY\": [\"manic psychosis\"]", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" \"PATHOLOGY\": []", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" \"PATHOLOGY\": [\"CNS\"]\n\n(Central Nervous System)", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" \"PATHOLOGY\": [\"\"]\n\n(No pathology or side effects were mentioned in the given context)", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" \"PATHOLOGY\": [\"diabetes\", \"diarrhea\"]", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" \"PATHOLOGY\": []\n\nThis statement does not mention any specific pathology or side effect. It discusses the serotonergic effects of SJW (Saint John's Wort), which is a pharmacological interaction mechanism.", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this text.)", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" {}\n\n\"PATHOLOGY\": []\n\nThis statement does not refer to any specific pathology or side effect. It is a general statement about the method of administration for herbal products.", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" \"PATHOLOGY\": []", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" {\"PATHOLOGY\": []}\n\nThis statement does not refer to a specific pathology or side effect. It is a factual statement about the expression of CYP3A4 and P-gp in human small intestinal enterocytes.", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" \"PATHOLOGY\": [\"neuropsychiatric disorders\"]\n\n\"DRUGS\": [\"neuropsychiatric drugs\"]", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" \"PATHOLOGY\": []", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" \"PATHOLOGY\": [\"kidney transplantation\"]", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" {\"PATHOLOGY\": []}", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology or side effect mentioned in the text)", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"PATHOLOGY\": [\"creatinine level\"]\n\nThis information does not specify a particular pathology or side effect, it is just reporting a value for creatinine level in the serum.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" \"PATHOLOGY\": []\n\nThis statement does not mention any specific pathology or side effect. It only discusses the potential for adverse effects from herb-drug interactions.", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {\"AUTHOR\": [\"MK\"]}", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" \"PATHOLOGY\": [\"graft rejection\"]", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" \"PATHOLOGY\": [\"immunosuppressive drugs\"]", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" {\"PATHOLOGY\": [\"\"]}\n\nThis statement does not mention any specific pathology or side effect. Parsley is a food, spice, and medicinal herb.", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" \"PATHOLOGY\": [\"sirolimus\"]\n\nThis information does not provide enough context to determine if there is an associated pathology or disease mentioned in the text.", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" {\"PATHOLOGY\": []}", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"PATHOLOGY\": [\"creatinine level\"]\n\nThis information does not specify a particular pathology or side effect, it is just reporting a value for creatinine level in the serum.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" \"PATHOLOGY\": [\"sirolimus\"]", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" \"PATHOLOGY\": []", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" No pathology or entity mentioned in this line.", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathologies or side effects. It only discusses the potential interaction between Epimedium sagittatum extract and sildenafil.", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" I'm unable to determine the meaning or relevance of \"et Zucc.\" in this context without additional information. It appears to be a citation, but without the full citation it's not possible to determine the pathology or entities mentioned in the referenced material.", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" \"PATHOLOGY\": []", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" No pathology mentioned in this text.", {}]], [841, "Maxim extract are available from the authors.", [" No pathology or entity was mentioned in this sentence.", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" \"PATHOLOGY\": []", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" \"PATHOLOGY\": []", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" \"PATHOLOGY\": []", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" No specific pathology or disease mentioned in this text.", {}]], [846, "They found a prevalence of 56.6%.", [" It is not clear what the prevalence of 56.6% refers to in the context of the provided text. No pathology or disease is mentioned in the given sentence. Therefore, no entry for \"PATHOLOGY\" field is needed for this sentence.", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" \"PATHOLOGY\": []", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" No pathologies or side effects were mentioned in this text.", {}]], [849, "A Spanish study reports Aloe vera [37].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in the given context.)", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" \"PATHOLOGY\": [\"liver\"]", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" \"PATHOLOGY\": []", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" \"PATHOLOGY\": [\"liver injury\"]", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" \"PATHOLOGY\": []", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" \"PATHOLOGY\": [\"inflammatory diseases\"]", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" \"PATHOLOGY\": []", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this text.)", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" \"PATHOLOGY\": [\"\"]\n\n(No relevant pathology or side effect mentioned in this text.)", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" \"PATHOLOGY\": [\"bleeding events\"]\n\n\"MEDICATION\": [\"anticoagulant\", \"platelet inhibiting co-medication\"]", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" \"PATHOLOGY\": [\"thrombin\"]", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" \"PATHOLOGY\": []\n\n\"ginseng\" is a common name for several different plants, including Panax ginseng, Asian ginseng, and American ginseng. It is used to refer to various traditional medicines made from these plants. Without additional context, it is not possible to determine which specific pathology or condition is being referred to in this article.", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" {\"AUTHOR\": [\"Seong\"]}\n\nIf you meant to provide a full citation for the authors of a study, please provide the last name and initials of all authors, followed by the year of publication and the title of the study in square brackets. For example:\n\n{\"AUTHOR\": [\"Seong J., Kim J., Lee S.\", \"2021\", \"Effect of Red Ginseng on Menopausal Symptoms: A Systematic Review\"]}\n\nIf you meant to mention the authors in a more general context, without providing a specific citation, then just include their last names.\n\n{\"AUTHOR\": [\"Seong\", \"Kim\", \"Lee\"]}", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" \"PATHOLOGY\": [\"HILI\"] (Hepatotoxicity of Unknown Origin)\n\nNote: HILI is a type of liver injury where the cause is unknown. It is not explicitly stated in the text that the liver injury is associated with tea consumption for everyone, but rather that there are only a few reported cases of HILI associated with tea consumption despite its widespread use. Therefore, it is important to note that the text does not imply that tea consumption is the cause of HILI for the general population, but rather that there have been a few reported cases of HILI in people who consume tea.", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" \"PATHOLOGY\": [\"HILI\"] (Hepatotoxicity Induced Liver Injury)", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" \"PATHOLOGY\": []", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" \"PATHOLOGY\": [\"\"]\n\n(No specific pathology or entity mentioned in this sentence)", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" \"PATHOLOGY\": [\"\"]\n\n(Note: No specific pathology or side effect was mentioned in this sentence)", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" \"PATHOLOGY\": [\"platelet aggregation\"]", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" \"PATHOLOGY\": [\"MTX\"]\n\n(Note: MTX stands for Methotrexate, which is a drug commonly used in the treatment of various conditions including rheumatoid arthritis and cancer.)", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" \"PATHOLOGY\": []", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" \"PATHOLOGY\": []", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" \"PATHOLOGY\": []", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" I will do my best to accurately identify and parse the entities mentioned in the text. However, I cannot guarantee 100% accuracy, especially when it comes to identifying specific species of plants or organisms.\n\n\"PATHOLOGY\": []", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" No entities found in this statement.", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" \"PATHOLOGY\": [\"diabetes\"]", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" \"PATHOLOGY\": []\n\nThis sentence does not mention any specific pathology or side effect. It is discussing the concept of herb-drug interactions.", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" \"PATHOLOGY\": []", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" \"PATHOLOGY\": []\n\nThis information does not refer to any specific pathology or side effect. It is describing a compound (allicin) found in garlic.", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" \"PATHOLOGY\": [\"diabetes\"]", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" \"PATHOLOGY\": [\"diabetes\"]", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" \"PATHOLOGY\": [\"diabetics\"]", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" \"PATHOLOGY\": [\"diabetes\"]", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" \"PATHOLOGY\": []", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" \"PATHOLOGY\": []", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" \"PATHOLOGY\": []", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" This statement is not related to pathologies or side effects. It is a disclaimer from the publisher.", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" \"PATHOLOGY\": [\"flatulence\", \"cough\", \"asthma\", \"bronchitis\", \"hysteria\", \"convulsions\"]", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" \"PATHOLOGY\": []\n\n(Note: No specific pathology or side effect was mentioned in this context.)", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" \"PATHOLOGY\": []\n\nThis passage does not mention any specific pathology or side effect. It only discusses the use of DEX as a probe for evaluating CYP3A and CYP2D6 activities.", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" \"PATHOLOGY\": []", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" No pathologies or side effects were mentioned in this text.\n\n\"PATHOLOGY\": []", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" No pathologies or side effects were mentioned in this text.\n\nTherefore, the output will be an empty dictionary.\n\n{\"PATHOLOGY\": []}", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" No pathologies or side effects were mentioned in this text.", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" 1]).{\"PATHOLOGY\": []}\n\nThis passage does not mention any specific pathology or side effect.", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" No pathology mentioned in this statement.", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" \"PATHOLOGY\": []", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {}\n\"PATHOLOGY\": []\n\nThis sentence does not provide any information about a specific pathology or condition. It is just stating that an in vitro study was followed by a clinical study to confirm the results.", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" \"PATHOLOGY\": []", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" \"PATHOLOGY\": [\"diarrhea\"]", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" \"PATHOLOGY\": [\"fatigue\", \"loose stools\"]", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"PATHOLOGY\": [\"List of pathologies or side effects found in text\"]}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.\nIn addition, red ginseng is thought to alleviate menopausal symptoms due to hormonal imbalance by maintaining the body's homeostasis during the menopausal period as these components work together. [/INST]{\"PATHOLOGY\": [\"menopausal symptoms\", \"menopausal\"]}</s> [INST] The determination of sample size was based on the previously reported prevalence of complementary medicine use in the literature;[15] accordingly, the study was continued to recruit 400 CKD and posttransplant patients who had been using medicinal herbs and herbal products during their kidney disease. [/INST]{\"PATHOLOGY\": [\"CKD\"]}</s> [INST] Some of the known interactions between selected antidiabetic drug and antidiabetic herbs are discussed in \u201cCommon herb\u2013drug interactions in diabetes\u201d [24\u201326]. [/INST]{\"PATHOLOGY\": [\"diabetes\"]}</s> [INST] In other cross-sectional and follow-up studies, a high lactate level at rest was associated with chronic diseases such as type 2 diabetes and hypertension [19,46]. [/INST]{\"PATHOLOGY\": [\"type 2 diabetes\", \"hypertension\"]}</s> [INST] The purpose of this study was to evaluate the inhibition of CYP2B6 enzyme activity by selected medicinal plant extracts used by HIV patients to treat HIV-associated opportunistic infections. [/INST]{\"PATHOLOGY\": [\"HIV\", \"HIV-associated opportunistic infections\"]}</s> [INST] TEXT HERE [/INST]"}